Erratum

Abstract

Department of Corrections| November 01 1999 Erratum Pediatr Rev (1999) 20 (11): 375. https://doi.org/10.1542/pir.20-11-375 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Erratum. Pediatr Rev November 1999; 20 (11): 375. https://doi.org/10.1542/pir.20-11-375 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search toolbar search search input Search input auto suggest filter your search All PublicationsAll JournalsPediatrics In ReviewPediatricsHospital PediatricsNeoReviewsAAP Grand RoundsAAP NewsAll AAP Sites Search Advanced Search Topics: adverse effects, analgesia (pain absence), brill's disease, drug dose, hydromorphone, naloxone, opioid analgesics, opioids, pain, pain management There are two drug dosage corrections to the article on pain relief that appeared in the March 1999 issue(Joseph MH, Brill J, Zeltzer LK. Pediatric pain relief in trauma. Pediatr Rev. 1999;20:75–84). On page 79 at the end of the first paragraph under the subhead Opiods, the second to the last sentence should read: Fortunately, for the majority of children, analgesia is reached prior to the onset of respiratory depression, and most adverse reactions are reversible with naloxone (0.1 mg/kg per dose up to a maximum of 2 mg). In Table 4 on page 80, the oral dose for hydromorphone should be:0.3 to 0.8 mg/kg q 4 to q 6 h. You do not currently have access to this content.